「Studies on the Enhancement of Antitumor Effect by Drug Combination in Molecular-Targeted Therapy of Cancer」の関連論文
-
Senescence-associated secretory phenotype promotes chronic ocular graft-vs-host disease in mice and humans (本文)
-
Lack of impact of the ALDH2 rs671 variant on breast cancer development in Japanese BRCA1/2‐mutation carriers
-
Cryptotanshinone suppresses tumorigenesis by inhibiting lipogenesis and promoting reactive oxygen species production in KRAS‑activated pancreatic cancer cells
-
Activation of the pentose phosphate pathway in macrophages is crucial for granuloma formation in sarcoidosis
-
The fruits of CD40 research in basic and clinical medicine will soon be harvested
-
Polarity switching of ovarian cancer cell clusters via SRC family kinase is involved in the peritoneal dissemination
-
Design and In vivo Evaluation of Novel mRNA Lipid Nanoparticles Beyond the Hepatocytes Towards a New Era of Personalized Gene Therapies [an abstract of entire text]
-
In silico study of RNA-seq and H3 Trimethylation ChIP-seq analysis in combination with laser-microdissection on human lung cancer cells
-
Mesenchymal stem cells induce tumor stroma formation and epithelial-mesenchymal transition through SPARC expression in colorectal cancer
-
Mesenchymal stem cells induce tumor stroma formation and epithelial-mesenchymal transition through SPARC expression in colorectal cancer
-
The Janus kinase inhibitor (baricitinib) suppresses the rheumatoid arthritis active marker gliostatin/thymidine phosphorylase in human fibroblast-like synoviocytes
-
Investigation of the mechanism for emergence of spatial heterogeneity of invading glioblastoma cells in the presence of perivascular factors (本文)
-
Fruit Fly, Drosophila melanogaster, as an In Vivo Tool to Study the Biological Effects of Proton Irradiation
-
Study on the role of CtBP2 in pancreatic β cell
-
Recapitulation of pro-inflammatory signature of monocytes with ACVR1A mutation using FOP patient-derived iPSCs
-
The ratio of CD8 + lymphocytes to tumor-infiltrating suppressive FOXP3 + effector regulatory T cells is associated with treatment response in invasive breast cancer
-
Basis research and development of DNA-targeted radio-platinum agents for Auger electron cancer therapy
-
MEK inhibition suppresses metastatic progression of KRAS-mutated gastric cancer (本文)
-
Construction of a single-cell atlas of non-hematopoietic cells in human lymph nodes and lymphoma for dissecting stromal remodeling
-
Tumor elimination by clustered microRNAs miR-306 and miR-79 via noncanonical activation of JNK signaling
-
CEBPγ facilitates lamellipodia formation and cancer cell migration through CERS6 upregulation
-
BRCA1 haploinsufficiency promotes chromosomal amplification under Fenton reaction-based carcinogenesis through ferroptosis-resistance
-
Tumour-immune microenvironment in duodenal-type follicular lymphoma
-
Latest classification of ependymoma in the molecular era and advances in its treatment: a review
-
Establishment of a mouse model of troglitazone-induced liver injury and analysis of its hepatotoxic mechanism
-
Bioinformatics and Functional Analyses Implicate Potential Roles for EOGT and L-fringe in Pancreatic Cancers
-
Real-world application of next-generation sequencing-based test for surgically resectable colorectal cancer in clinical practice (本文)
-
Analysis of disease model iPSCs derived from patients with a novel Fanconi anemia-like IBMFS ADH5/ALDH2 deficiency
-
Autotaxin in ascites promotes peritoneal dissemination in pancreatic cancer
-
CD44v9 Induces Stem Cell-Like Phenotypes in Human Cholangiocarcinoma
-
Evolutionary histories of breast cancer and related clones
-
T cell receptor-engineered T cells derived from target human leukocyte antigen-DPB1-specific T cell can be a potential tool for therapy against leukemia relapse following allogeneic hematopoietic cell transplantation
-
Cryptotanshinone is a candidate therapeutic agent for interstitial lung disease associated with a BRICHOS-domain mutation of SFTPC
-
Pharmacological Evaluation of GPR40 Full Agonists in Metabolic Disease Models
-
Immunosuppressants Tacrolimus and Sirolimus revert the cardiac antifibrotic properties of p38-MAPK inhibition in 3D-multicellular human iPSC-heart organoids
-
Myogenetic Oligodeoxynucleotides as Anti-Nucleolin Aptamers Inhibit the Growth of Embryonal Rhabdomyosarcoma Cells
-
Gut bacteria identified in colorectal cancer patients promote tumourigenesis via butyrate secretion
-
Malfunctioning CD106-positive, short-term hematopoietic stem cells trigger diabetic neuropathy in mice by cell fusion.
-
Vascular Shutdown by Photodynamic Therapy Using Talaporfin Sodium
-
Clinicopathological significance of EGFR pathway gene mutations and CRTC1/3–MAML2 fusions in salivary gland mucoepidermoid carcinoma
-
Metronomic photodynamic therapy using an implantable LED device and orally administered 5-aminolevulinic acid
-
Ror1 is expressed inducibly by Notch and hypoxia signaling and regulates stem cell-like property of glioblastoma cells
-
Studies on the roles of EMT-associated microRNAs in cervical cancer and aggressive endometrial cancer
-
Novel Therapeutic Impact of Isorhamnetin for the Upstream Treatment of Atrial Fibrillation
-
Repurposing bromocriptine for Aβ metabolism in Alzheimer’s disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer’s disease with presenilin 1 (PSEN1) mutations
-
Aging-associated and CD4 T-cell–dependent ectopic CXCL13 activation predisposes to anti–PD-1 therapy-induced adverse events
-
Irbesartan, an angiotensin II type 1 receptor blocker, inhibits colitis-associated tumourigenesis by blocking the MCP-1/CCR2 pathway
-
Transcutaneous carbon dioxide application suppresses the expression of cancer-associated fibroblasts markers in oral squamous cell carcinoma xenograft mouse model
-
Diagnostic significance of apical membranous and cytoplasmic dot-like CD26 expression in encapsulated follicular variant of papillary thyroid carcinoma : a useful marker for capsular invasion
-
Phase 3 Trial of Concizumab in Hemophilia with Inhibitors